Zajda Janusz, Farag Fawzy
MOCONTI Ltd, Urological Office, Warsaw, Poland ; IATROS NZOZ, Department of Urology Warsaw, Poland ; First two authors equally contributed to the manuscript.
Department of Urology, Hamad Medical Corporation, Doha, Qatar.
Cent European J Urol. 2015;68(3):334-8. doi: 10.5173/ceju.2015.541. Epub 2015 Sep 26.
To evaluate the efficacy and durability of Urolastic, a new urethral bulking agent in women with stress urinary incontinence (SUI), after a follow-up of 24-months.
A follow-up study of women with SUI who received a Urolastic injection and successfully passed the 12-month follow-up. Assessment included the Stamey Grade, 1-h Pad weight test, and the International quality of life (I-QoL) score.
Nineteen women who completed the 12-month follow-up were invited for the 24-month follow-up study. One patient did not respond to the correspondence. Four of the 18 patients who responded to the correspondence reported removal of the Urolastic implant at another facility, based on their desire. The explanation for this removal was painful intercourse (n = 1) or less than optimal dryness (n = 3). The overall objective improvement in continence status at 24-months was 66% compared to the 89% at the 12-month follow-up, while in addition the 1-h pad weight test showed >50% reduction in pad weight in 66% of patients compared to 84% at the 12-month follow-up. Adverse events reported were urinary tract infection (n = 1), local genital infection with erosion into the vagina (n = 1), painful intercourse (n = 2), and urgency (n = 4).
Urolastic is comparable to other bulking agents in terms of durability, efficacy, and complications.
为评估新型尿道填充剂Urolastic在压力性尿失禁（SUI）女性患者中随访24个月后的疗效和持久性。
对接受Urolastic注射并成功通过12个月随访的SUI女性患者进行随访研究。评估包括Stamey分级、1小时护垫重量试验和国际生活质量（I-QoL）评分。
19名完成12个月随访的女性被邀请参加24个月随访研究。1名患者未回复信件。在回复信件的18名患者中，有4名患者根据自身意愿在其他机构取出了Urolastic植入物。取出的原因是性交疼痛（1例）或干燥情况未达最佳（3例）。与12个月随访时的89%相比，24个月时尿失禁状态的总体客观改善率为66%，此外，1小时护垫重量试验显示，66%的患者护垫重量减少>50%，而12个月随访时为84%。报告的不良事件包括尿路感染（1例）、局部生殖器感染伴阴道糜烂（1例）、性交疼痛（2例）和尿急（4例）。
在持久性、疗效和并发症方面，Urolastic与其他填充剂相当。
